Profitability
Weight: 20%
D-
30
- 5yr Avg ROIC -52.6%
- Operating Margin Trend +272.75 pp/yr
AMLX
Amylyx Pharmaceuticals, Inc.
AlphaQuality composite grade, weighted for stable earnings power businesses.
⚠ 4 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a stable earnings power business.
Grade overrides the 29.7 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -69.4%
- 5yr Share-Count CAGR 10.9%
Growth Quality
Weight: 15%
F
20
- Revenue-Growth Years (5) 1/5
Cash Generation
Weight: 15%
F
10
- 5yr FCF Margin -336.6%
- 5yr FCF/NI Conversion 0.22x
Balance Sheet
Weight: 20%
C
55
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) 30.00x
- Altman Z-Score 82.02
Stability
Weight: 15%
C
54
- Negative-Revenue Years (5) 1/5
- Piotroski F-Score 3
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.2 of 2 gurus held; 1 added; 1 trimmed.
- Holders
- 2
- Avg Δ position
- +21.0%
- New buys
- 0
- Full exits
- 0